Cancer remains employers’ largest unmanaged cost risk. But it’s losing daily executive attention to trendier benefits topics like GLP-1s and mental health. That drift is creating a structural gap, one that quietly drives higher spend and worse outcomes for employees.
Here’s what most benefits strategies miss: Cancer costs aren’t driven by drugs alone. They escalate when treatment decisions are made without the subspecialty expertise that precision oncology requires. The wrong call early on can cascade across every line of therapy, hospitalization, and complication that follows.
In this session, you’ll learn:
- How executives lose focus on cancer, their top cost driver
- Why 94% of employers value expert oncology review, yet only 6% offer it
- Strategies to close this gap without adding complexity to employers’ benefits strategy
- What early results look like when subspecialty expertise is introduced at the right moment
Whether you’re shaping benefits, guiding clinical strategy, or advising employers, this session will give you the data and the framework to put cancer back on the executive radar.
